Patient characteristics in the long- and short-term dual antiplatelet therapy groups
| Long-term DAPT (n=191) | Short-term DAPT (n=105) | P value | |
| Age: mean±SD | 60.4±13.1 | 60.1±12.9 | 0.874 |
| Man: n (%) | 51 (26.7) | 35 (33.3) | 0.285 |
| Previous SAH: n (%) | 18 (9.4) | 11 (10.5) | 0.931 |
| Previous hemorrhagic stroke: n (%) | 6 (3.1) | 3 (2.9) | 1.000 |
| Previous ischemic stroke: n (%) | 13 (6.8) | 6 (5.7) | 0.905 |
| Risk Factors: n (%) | |||
| Hypertension | 93 (48.7) | 48 (45.7) | 0.712 |
| Diabetes | 13 (6.8) | 3 (2.9) | 0.242 |
| Dyslipidemia | 67 (35.1) | 30 (28.6) | 0.312 |
| Smoking habit | 27 (14.1) | 16 (15.2) | 0.932 |
| Target aneurysm, symptoms: n (%) | 0.030 | ||
| Unruptured (asymptomatic) | 169 (88.5) | 93 (88.6) | |
| Unruptured (symptomatic) | 12 (6.3) | 1 (1.0) | |
| Ruptured (15 days after onset) | 10 (5.2) | 11 (10.5) | |
| Target aneurysm, locations: n (%)* | |||
| ICA-paraclinoid | 67 (35.1) | 41 (39.0) | |
| ICA-PcomA | 20 (10.5) | 16 (15.2) | |
| MCA bifurcation | 7 (3.7) | 4 (3.8) | |
| AcomA | 25 (13.1) | 10 (9.5) | |
| VA | 23 (12.0) | 15 (14.3) | |
| VA-PICA | 6 (3.1) | 2 (1.9) | |
| BA bifurcation | 19 (9.9) | 9 (8.6) | |
| PCA | 1 (0.5) | 1 (1.0) | |
| Others (anterior circulation) | 1 (1.5) | 2 (1.9) | |
| Target aneurysm, maximum diameter (mm): mean±SD | 8.06±4.32 | 7.54±3.24 | 0.280 |
| Target aneurysm, maximum diameter <10mm: no (%) | 152 (79.6) | 87 (82.9) | 0.596 |
| Patients with non-target aneurysm in this study: n (%) | 50 (26.2) | 17 (16.2) | 0.069 |
| Radiographic outcome: n (%) | 0.183 | ||
| Complete occlusion | 75 (39.3) | 33 (31.4) | |
| Neck remnant | 64 (33.5) | 33 (31.4) | |
| Aneurysm filling | 52 (27.2) | 39 (37.1) | |
| Deployed stent: n (%) | 0.175 | ||
| Enterprise VRD | 3 (1.6) | 0 (0.0) | |
| Enterprise 2 | 14 (7.3) | 19 (18.1) | |
| Neuroform EZ | 13 (6.8) | 7 (6.7) | |
| Neuroform Atas | 57 (29.8) | 28 (26.7) | |
| LVIS | 69 (36.1) | 38 (36.2) | |
| LVIS Jr | 26 (13.6) | 13 (12.4) | |
| Double stents† | 3 (1.6) | 0 (0.0) | |
| Pipeline | 4 (2.1) | 0 (0.0) | |
| Unknown | 2 (1.0) | 0 (0.0) | |
| ARU at registration: mean±SD | 455.6±73.7 | 445.9±82.5 | 0.346 |
| PRU at registration: mean±SD | 173.7±75.6 | 176.4±90.5 | 0.803 |
| Duration of DAPT (weeks): mean±SD | 45.0±15.0 | 13.3±4.6 | <0.001 |
Characteristics of Long term DAPT group and Short term DAPT group.
*includes patients with multiple aneurysms
†one patient was treated with Enterprise VRD and Neuroform Atlas stents, one with LVIS Jr and LVIS stents, and one with ELVIS and Neuroform Atlas stentsDAPT, dual antiplatelet therapy
AcomA, anterior communicating artery; ARU, aspirin reaction units; BA, basilar artery; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; PcomA, posterior communicating artery; PICA, posterior inferior cerebellar artery; PRU, P2Y12 reaction units; SAH, subarachnoid hemorrhage; VA, vertebral artery.